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Introduction: Most hepatocellular carcinomas (HCC) develop in a background of underlying liver disease including
chronic hepatitis B. However, the effect of antiviral therapy on the long-term outcome of patients with hepatitis B
virus (HBV)-related HCC treated with chemoembolization is unclear. This study aimed to evaluate the survival
benefits of anti-HBV therapy after chemoembolization for patients with HBV-related HCC.
Methods: A total of 224 HCC patients who successfully underwent chemoembolization were identified, and their
survival and other relevant clinical data were reviewed. Kaplan-Meier and Cox regression analyses were performed
to validate possible effects of antiviral treatment on overall survival (OS).
Results: The median survival time (MST) was 15.9 (95% confidence interval [CI], 9.5–27.7) months in the antiviral
group and 9.6 (95% CI, 7.8–13.7) months in the non-antiviral group (log-rank test, P = 0.044). Cox multivariate
analysis revealed that antiviral treatment was a prognostic factor for OS (P = 0.008). Additionally, a further analysis
was based on the stratification of the TNM tumor stages. In the subgroup of early stages, MST was significantly
longer in the antiviral-treatment group than in the non-antiviral group (61.8 months [95% CI, 34.8 months to
beyond the follow-up period] versus 26.2 [95% CI, 14.5–37.7] months, P = 0.012). Multivariate analysis identified
antiviral treatment as a prognostic factor for OS in the early-stage subgroup (P = 0.006). However, in the subgroup
of advanced stages, MST of the antiviral-treated group was comparable to that of the non-antiviral group (8.4 [95%
CI, 5.2–13.5] months versus 7.4 [95% CI, 5.9–9.3] months, P = 0.219). Multivariate analysis did not indicate that antiviral
treatment was a significant prognostic factor in this subgroup.
Conclusion: Antiviral treatment is associated with prolonged OS time after chemoembolization for HCC, especially in
patients with early-stage tumors.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer in men and the seventh most common in
women, and it is the third most common cause of death
from cancer worldwide [1]. In 2010, the estimates of
new liver cancer cases and deaths were 358,840 and
312,432, respectively, in China [2]. Most HCCs develop
based on underlying liver diseases. In Japan, most
European countries, and America, approximately 60% of
HCC cases are attributed to chronic infection with
hepatitis C virus (HCV) [3]. However, in most Asian
countries, especially in China, hepatitis B virus (HBV)
infection plays the primary role in the etiology of HCC
and is frequently observed in HCC patients [4,5]. High
levels of serum HBV DNA are associated with an in-
creased risk of developing HCC [6]. Additionally, in
HBV-related HCC, high levels of serum HBV DNA ap-
pear to be associated with a poor prognosis [7-9]. Thus,
careful management of HBV is required in the treatment
of hepatic malignancies [10].
Transarterial chemoembolization (TACE) is the most
widely used palliative treatment for unresectable HCC;
based on clinical evidence, it has shown survival benefits
[11,12]. In some studies, TACE has been used as a
curative-intent therapy in some selected patients with
early-stage HCCs [13-17]. As TACE is a locoregional
therapy that is different from systemic chemotherapy, it
has the potential to cause HBV reactivation [18,19]. Our
previous study revealed that antiviral therapy could re-
duce the risk of HBV reactivation after TACE [20]. How-
ever, the long-term effect of the antiviral treatment on
the overall survival (OS) of patients with HCCs undergo-
ing TACE remains unclear, and there are currently few
reports concerning this issue.
In this study, we aimed to evaluate the long-term ef-
fect of antiviral therapy on OS in a large cohort treated
with TACE for HCC.
Patients and Methods
Patients and inclusion criteria
This retrospective study was approved by the Institutional
Review Board (IRB) at the Sun Yat-sen University Cancer
Center. Patients who were initially diagnosed with
hepatitis B surface antigen (HBsAg)-positive HCC
and received TACE between January 2008 and December
2008 at the Hepatobiliary Department of Sun Yat-sen
University Cancer Center were selected for this
investigation.
Baseline examinations within 1 week before TACE
included serum HBV DNA quantification; detection
of HBsAg, hepatitis B surface antibody (HBsAb),
hepatitis B core antibody (HBcAb), hepatitis B e antigen
(HBeAg), hepatitis B e antibody (HBeAb), and anti-HCV
antibody (HCV Ab); serum liver function tests (alanineaminotransferase [ALT], aspartate aminotransferase [AST],
alkaline phosphatase, total bilirubin [TBIL], and albumin
[ALB]); creatinine levels; prothrombin time (PT); activated
partial thromboplastin time (APTT); alpha-fetoprotein
(AFP) levels; complete blood counts; and chest radiog-
raphy. Serum HBV viral loads were measured by using
quantitative fluorescence polymerase chain reaction (PCR)
detection kit (DaAn Gene Corporation, Guangzhou,
China) for HBV DNA with a lower detection limit of
100 IU/mL. The diagnosis of HCC was based on the cri-
teria established by the European Association for the Study
of the Liver [21]. Tumor characteristics and TNM stage
(Union for International Cancer Control [UICC], 7th
version) were evaluated by imaging and/or the intra-
operative observation. The HBV DNA status changes
after treatment were evaluated within 1 to 5 months
after the initial TACE. The changes of HBV DNA levels
were grouped into two categories, HBV reactivation and
non-reactivation. HBV reactivation was defined as a ≥10-
fold increase in the HBV DNA level compared with
baseline or the appearance of HBV DNA from an
undetectable level at baseline and a post-TACE HBV
DNA level >200 IU/mL [19,20,22,23]. The other situ-
ations were grouped into non-reactivation.
The inclusion criteria were as follows: a positive result
for HBsAg examination, naïve anti-HBV treatment
before the current TACE, adequate baseline liver
function (Child-Pugh grade A), adequate renal func-
tion (serum creatinine < 124 μmol/L), proper baseline
Eastern Cooperative Oncology Group performance
status (ECOG PS) grades (scores 0–2), and well tolerance
of TACE. Exclusion criteria were as follows: a negative
result for HBsAg examination, evidence of co-infection
with other hepatotropic viruses, human immunodefi-
ciency virus (HIV) infection, any prior treatment for
HCC, Child-Pugh grade B or C liver function, any other
malignancy, a concurrent non-malignant severe illness, a
history of interferon administration, or a history of
corticosteroid administration. Specifically, to rule out
possible influences caused by the TACE procedure,
the patients with severe complications or severe ad-
verse events shortly after TACE (within 1 month) were
excluded.
During the study period in our department, there
were only 15 patients with Child-Pugh grade B liver
function who received an initial treatment of TACE.
The number was too small to maintain the homogen-




TACE was performed as described previously [19,24].
When the catheter tip was advanced to the tumor-feeding
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mixed lipiodol were then slowly injected. Gelatin
sponge particles were injected in some sessions if the
chemoembolized artery territory did not show stagnant
flow. The chemotherapeutic agents included epirubicin
(60 mg/session) and/or mitomycin (6 mg/session), carbo-
platin (300 mg/session), lobaplatin (50 mg/session), and
floxuridine (500 mg/session). The selection of various
combinations of anticancer agents, lipiodol emulsion
dosage, and use of gelform was made on a case-by-case
basis. The cycles of TACE were recorded.
Subsequent treatment
After the initial TACE, the patients were followed up
and received subsequent treatment, including local
ablation, hepatectomy, or sorafenib therapy on a
case-by-case basis. In the current study, no patients
were offered liver transplantation. Follow-up ended
on October 1, 2014.
Oral antiviral drugs
Of the 224 involved patients, 80 received nucleotide or
nucleoside analogs (NUCs) after TACE, and 144 did not.
The HBV DNA levels were monitored. Of the 80 pa-
tients, 39 received entecavir (ETV) only, and 37 received
lamivudine (LAM) only. The other 4 patients initially
received LAM treatment. However, because HBV resist-
ance appeared, adefovir dipivoxil (ADV) was added in
2 cases, and LAM was replaced by ETV in the other
2 cases. The choices of LAM and ETV in the current
study were based on the availability of agents and the in-
surance coverage for those agents. The median antiviral
time was 13.8 months (range, 1.2 to 82.0 months). No
serious adverse events related to antiviral treatment were
observed.
Statistical analysis
Demographic data (mean, standard deviation, median,
interquartile [P25, P75], and percentage) were calculated.
Analyses were conducted using the independent
Student’s t test (Mann–Whitney for non-normal dis-
tributions), ANOVA, Chi-square test, and Fisher's
exact test as appropriate. Kaplan-Meier methods and
log-rank tests were used for survival analysis. OS was
calculated from the date of initiation of TACE to the
date of death or the last follow-up. The Cox propor-
tional hazards model was used in the univariate survival
analysis to determine the association of individual clinical
variables with OS. All variables with P < 0.1, in addition
to age and sex, were subsequently subjected to the multi-
variate Cox regression model to determine the hazards
ratios (HRs) and the independence of effects. The pro-
portional hazards assumption was checked by graphic in-
spection of the linearity of the hazards over time, log-logplots, and plotting Schoenfeld residuals over time. A
P value less than 0.05 was considered statistically sig-
nificant. All statistical tests were two-sided. Data were
analyzed by using the SAS 9.1 software (SAS Institute,
Cary, NC, USA).
Results
Study population and baseline clinical characteristics
The clinical characteristics of the study population are
shown in Table 1. There were 209 male and 15 female
patients with a median age of 49.5 years (range, 16 to
80 years); 53 patients were HBeAg-positive, and 171
were HBeAg-negative. There were 19, 49, and 12 pa-
tients who received hepatectomy, local thermal ablation,
and sorafenib treatment after TACE, respectively. Ac-
cording to the UICC TNM staging system, there were
46, 25, 68, 63, and 22 patients with stages I, II, IIIa,
IIIb + IIIc, and IV HCC, respectively (as there were
only 3 patients categorized into stage IIIc, we com-
bined stages IIIc and IIIb).
The mean baseline HBV DNA level in the antiviral
treatment group was significantly higher than that in the
non-antiviral treatment group (5.50 ± 1.58 log10IU/mL
versus 4.48 ± 1.92 log10IU/mL, P < 0.01), which may have
been because antiviral treatment was selectively used
for patients with high viral loads. There were 53.8%
(43 of 80) of patients undergoing more than one ses-
sion of TACE in antiviral treatment group, which
was significantly higher than the percentage in the non-
antiviral treatment group (33.3%, 48 of 144) (P = 0.003).
The frequency of local thermal therapy after TACE in the
antiviral treatment group was 28.8% (23 of 80), higher
than that in the non-antiviral treatment group (18.1%, 26
of 144) (P = 0.064). One to 5 months after the initial
TACE, there were 2 of 80 cases (2.5%) of HBV reactiva-
tion in the antiviral therapy group and 20 of 144 (13.9%)
in the non-antiviral therapy group (P < 0.001).
The median follow-up period for all patients was
9.9 months (range, 1.3 to 82.0 months). The median sur-
vival time was 11.0 months (95% CI, 9.2 to 15.9 months).
A total of 177 patients died, including 59 patients in
antiviral treatment group and 118 patients in non-
antiviral treatment group. The 0.5-, 1-, 2-, 3-, 4-, 5-, and
6-year OS rates for all patients were 69.7%, 47.9%,
32.3%, 23.2%, 20.1%, 16.9%, and 14.4%, respectively.
Univariate and multivariate analyses of factors contributing
to OS
The univariate analysis identified that the following fac-
tors were significantly associated with OS time for all
cases: age, sex, TNM stage, AST, ALB, TBIL, AFP, anti-
viral treatment, subsequent local ablation, and resection.
The multivariate analysis revealed that sex, TNM stage,
ALB, antiviral treatment, local ablation, and resection
Table 1 The baseline characteristics of all selected patients with hepatocellular carcinoma (HCC)
Characteristic Total (n = 224) Antiviral treatment
group (n = 80)
Non-antiviral treatment
group (n = 144)
P valuec
Sex (males:females) 209:15 78:2 131:13 0.092
Age (years)a 49.5 (38.5, 58.0) 48.0 (39.5, 56.0) 50.5 (38.0, 59.0) 0.574
WBC (×109/L) 6.66 ± 2.12 6.38 ± 1.85 6.82 ± 2.25 0.286
HBG (g/L) 137.91 ± 20.28 137.90 ± 22.36 137.90 ± 19.10 0.987
PLT (×109/L) 179.91 ± 84.16 170.30 ± 88.10 185.24 ± 81.71 0.076
ALT (U/L) 58.38 ± 40.62 65.28 ± 44.99 54.54 ± 37.60 0.081
AST (U/L) 84.89 ± 62.44 91.17 ± 63.80 81.40 ± 61.62 0.125
ALB (g/L) 40.10 ± 4.40 39.30 ± 4.55 40.54 ± 4.26 0.032
TBIL (μmol/L) 16.44 ± 7.61 17.73 ± 8.49 15.72 ± 6.99 0.059
AFP (ng/mL)a 1301 (50, 38,398) 1436 (53, 37,546) 1210 (50.74, 39,410) 0.820
AFP (<1,000 ng/mL:>1,000 ng/mL) 108:116 39:41 69:75 0.905
PT (s) 12.58 ± 2.08 12.83 ± 2.05 12.44 ± 2.09 0.052
APPT (s) 27.95 ± 3.85 28.22 ± 3.69 27.80 ± 3.94 0.278
HBeAg (positive:negative) 53:171 24:56 29:115 0.096
HBV DNA (log10IU/mL) 4.85 ± 1.86 5.50 ± 1.58 4.48 ± 1.92 <0.001
UICC TNM stage (I:II:IIIa:IIIb + IIIc:IV) 46:25:68:63:22 9:14:25:26:6 37:11:43:37:16 0.024
TNM stage (early:advanced) 71:153 23:57 48:96 0.480
Cycles of TACE (one:more than one) 133:91 37:43 96:48 0.003
Resection after TACE (yes:no) 19:205 7:73 12:132 0.915
Local ablation after TACE (yes:no) 49:175 23:57 26:118 0.064
Sorafenib therapy after TACE (yes: no) 12:212 6:74 6:138 0.288
Subsequent therapyb after TACE (yes:no) 67:157 30:50 37:107 0.065
Chemotherapeutic agents(epirubicin only:>2 agents) 53:171 18:62 35:109 0.761
aThe values are presented as median followed by interquartile (P25 and P75) in the parentheses. bSubsequent therapy means any treatment after TACE, including
resection, local ablation, or sorafenib therapy. cDifferences between the antivirus group and the non-antivirus group. WBC, white blood cells; HBG, hemoglobin;
PLT, platelets; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, serum albumin; TBIL, total bilirubin; AFP, α-fetoprotein; PT, prothrombin time;
APTT, activated partial thromboplastin time; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; UICC TNM, International Union Against Cancer tumor-node-metastasis;
TACE, transcatheter arterial chemoembolization.
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(Table 2).
The median survival times in the antiviral treatment
group and the non-antiviral treatment group were
15.9 months (95% CI, 9.5 to 27.7 months) and
9.6 months (95% CI, 7.8 to 13.7 months), respectively.
Survival time was significantly longer in the antiviral
treatment group than in the non-antiviral treatment
group (P = 0.044) (Figure 1).
The tumor stage also significantly affected the OS
time. Figure 2A shows that TNM stage was significantly
associated with OS time. When we categorized TNM
stage into two main types, early stage (stages I and II)
and advanced stage (stages III and IV), the tendency
was still obvious and significant (Figure 2B). The me-
dian survival times were 34.8 (95% CI, 24.7–53.8)
months for patients with early-stage diseases and 8.2
(95% CI, 6.0–9.4) months for patients with advanced-
stage diseases (P < 0.001).Stratification analysis based on the UICC TNM staging
TNM early stage
The characteristics of 71 patients with early-stage dis-
eases are summarized in Table 3. The median survival
time for the antiviral treatment group was 61.8 months
(95% CI, 34.8 months to beyond the follow-up period),
and 26.2 months (95% CI, 14.5–37.7 months) for the
non-antiviral group (log-rank test, P = 0.012). Antiviral
therapy was associated with significantly longer survival
time compared with non-antiviral therapy in HCC pa-
tients with early-stage diseases who underwent TACE
(Figure 3A).
Univariate analysis identified that the following factors
were significantly associated with OS for the TNM early-
stage patients: AST, AFP, antiviral treatment, local ther-
apy, and resection. Multivariate analysis revealed that
sex, antiviral treatment, local ablation, and resection
were significant prognostic factors associated with OS
(Table 4).
Table 2 The relationship between clinical characteristics and overall survival in 224 patients: Cox’s regression analysis
Variable Univariate analysis Multivariate analysis
P value Hazard ratio 95% CI P value
Age 0.013 0.988 0.975–1.002 0.084
Sex 0.020 2.424 1.139–5.156 0.022
HBV DNA (log10IU/mL) 0.602 – – –
ALT 0.607 – – –
TNM stage (early:advanced) <0.001 2.031 1.410–2.925 <0.001
Cycles of TACE 0.346 – – –
AST <0.001 1.001 0.998–1.005 0.496
ALB 0.043 0.950 0.913–0.988 0.010
TBIL 0.028 1.007 0.986–1.029 0.511
AFP <0.001 1.400 0.979–2.003 0.066
APTT 0.259 – – –
Antiviral treatment 0.044 0.635 0.454–0.888 0.008
Local ablation <0.001 0.241 0.133–0.436 <0.001
Resection <0.001 0.298 0.148–0.599 0.001
HBeAg 0.977 – – –
PT 0.746 – – –
Sorafenib therapy 0.825 – – –
Chemotherapeutic agents (epirubicin only:>2 agents) 0.798 – – –
CI, confidence interval. Other abbreviations as in Table 1.
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The characteristics of 153 patients with advanced-stage
diseases are summarized in Table 3. The Kaplan-Meier
analysis revealed that there was no significant differ-
ence in OS between the antiviral treatment and the
non-antiviral treatment groups in the patients withFigure 1 Kaplan-Meier curves of overall survival for 224 hepatocellular carc
in the antiviral treatment group was significantly higher than that in the no
confidence interval.advanced-stage diseases (8.4 [95% CI, 5.2–13.5] months
versus 7.4 [95% CI, 5.9–9.3] months, P = 0.219 by log-rank
test) (Figure 3B).
Univariate analysis identified that AST, TBIL, local
ablation, and resection were significantly associated
with OS for the patients with advanced-stage diseases.inoma (HCC) patients with or without antiviral treatment. Survival rate
n-antiviral treatment group. TACE, transarterial chemoembolization; CI,
Figure 2 Kaplan-Meier curves of overall survival for 224 patients with HCC at different stages. A, the tumor stages were categorized into TNM
stages I, II, IIIa, IIIb + IIIc, and IV. B, the tumor stages were categorized into TNM early stage (including stages I and II) and advanced stage
(including stages III and IV). TACE, transarterial chemoembolization; CI, confidence interval.
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Table 3 The baseline characteristics of 224 patients with HCC based on the stratification with the TNM staging system
Characteristic TNM early stage TNM advanced stage









Sex (males:females) 108:11663:8 22:1 41:7 0.261 146:7 56:1 90:6 0.198
Agea (years) 54.5 (45.0, 62.0) 55.0 (48.0, 62.0) 52.5 (42.0, 62.5) 0.690 46.0 (36.5, 57.0) 45.0 (37.0, 53.0) 48.0 (36.0, 57.0) 0.427
WBC (×109/L) 6.29 ± 1.91 6.38 ± 1.94 6.25 ± 1.91 0.649 6.84 ± 2.20 6.38 ± 1.83 7.11 ± 2.35 0.090
HBG (g/L) 139.02 ± 19.74 140.77 ± 17.61 138.18 ± 20.81 0.609 137.39 ± 20.57 136.79 ± 24.06 137.74 ± 18.30 0.783
PLT (×109/L) 153.37 ± 79.37 147.78 ± 77.98 156.04 ± 80.70 0.746 192.22 ± 83.71 179.39 ± 90.93 199.84 ± 78.62 0.052
ALT (U/L) 50.19 ± 32.14 55.11 ± 28.20 47.83 ± 33.89 0.136 62.18 ± 43.58 69.38 ± 49.83 57.90 ± 39.06 0.289
AST (U/L) 65.63 ± 44.32 60.38 ± 29.26 68.14 ± 50.05 0.883 93.83 ± 67.54 103.59 ± 69.70 88.03 ± 65.90 0.092
ALB (g/L) 40.14 ± 4.59 40.40 ± 4.82 40.02 ± 4.52 0.976 40.08 ± 4.32 38.86 ± 4.41 40.80 ± 4.13 0.009
TBIL (μmol/L) 15.72 ± 6.68 16.09 ± 6.76 15.54 ± 6.71 0.811 16.77 ± 8.00 18.40 ± 9.07 15.81 ± 7.16 0.056
AFPa (ng/mL) 197.70 (7.72, 3065) 63.68 (5.12, 804.7) 650 (9.33, 9419.50) 0.074 4682 (202.80, 76308) 7097 (363.6, 85094) 4571 (106.58, 67557.50) 0.522
AFP (<1,000 ng/mL:>1,000 ng/mL) 47:24 19:4 28:20 0.043 61:92 20:37 41:55 0.352
PT (s) 12.46 ± 2.34 12.77 ± 2.47 12.31 ± 2.28 0.373 12.63 ± 1.96 12.85 ± 1.88 12.50 ± 2.00 0.103
APPT (s) 27.66 ± 3.76 27.57 ± 4.35 27.71 ± 3.50 0.749 28.08 ± 3.89 28.48 ± 3.39 27.85 ± 4.16 0.127
HBeAg positive:negative 15:56 7:16 41:78:40 0.184 38:115 17:40 21:75 0.271
HBV DNA (log10 IU/mL) 4.58 ± 1.93 5.24 ± 1.97 4.26 ± 1.84 0.033 4.97 ± 1.83 5.60 ± 1.39 4.59 ± 1.95 0.001
Cycles of TACE (one:more than one) 43:28 8:15 35:13 0.002 90:63 29:28 61:35 0.124
Resection after TACE (yes:no) 11:60 3:20 8:40 1.000 8:145 4:53 5:92 0.471
Local therapy after TACE (yes:no) 29:42 12:11 17:31 0.179 20:133 11:46 9:87 0.078
Sorafenib use after TACE (yes:no) 5:66 3:20 2:46 0.320 7:146 3:54 4:92 0.712
Subsequent therapy (yes:no) 37:34 15:8 22: 26 0.126 30:123 15:42 15:81 0.107
Chemotherapeutic agents
(epirubicin only: >2 agents)
19:52 5:18 14:34 0.508 34:119 13:44 21:75 0.893











Figure 3 Kaplan-Meier subgroup analysis stratified according to TNM stage. A, for the 71 patients with TNM early-stage diseases (including stages I
and II), the survival rate in the antiviral treatment group was significantly higher than that in the non-antiviral treatment group. B, for the 153
patients with TNM advanced stage diseases (including stages III and IV), there was no significant difference between the antiviral and non-antiviral
treatment groups. TACE, transarterial chemoembolization; CI, confidence interval.
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Table 4 The relationship between clinical characteristics and overall survival in HCC patients based on the stratification
with the TNM staging system: Cox’s regression analysis






P value Hazard ratio 95% CI P value P value Hazard ratio 95% CI P value
Age 0.821 1.001 0.978–1.025 0.920 0.075 0.975 0.956–0.995 0.016
Sex 0.158 3.946 1.332–11.690 0.013 0.372 1.891 0.641–5.577 0.248
HBV DNA (log10IU/mL) 0.408 – – – 0.328 – – –
ALT 0.445 – – – 0.994 – – –
Cycles of TACE 0.885 – – – 0.070 1.305 0.836–2.037 0.242
AST 0.016 1.004 0.996–1.012 0.363 0.001 1.002 0.999–1.005 0.201
ALB 0.149 – – – 0.066 0.945 0.893–1.000 0.051
TBIL 0.711 – – – 0.024 1.008 0.982–1.035 0.555
AFP 0.022 2.087 0.920–4.736 0.078 0.067 1.144 0.741–1.767 0.545
APTT 0.709 – – – 0.068 0.988 0.942–1.037 0.633
Antiviral treatment 0.012 0.372 0.183–0.756 0.006 0.219 – – –
Local ablation 0.005 0.280 0.136–0.577 0.001 <0.001 0.211 0.095–0.472 <0.001
Resection 0.023 0.152 0.049–0.473 0.001 0.008 0.308 0.118–0.801 0.016
HBeAg 0.958 – – – 0.621 – – –
PT 0.241 – – – 0.765 – – –
Sorafenib therapy 0.943 – – – 0.782 – – –
Chemotherapeutic agents
(epirubicin only: >2 agents)
0.211 – – – 0.073 0.881 0.540–1.439 0.613
Abbreviations as in Table 1.
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resection were significant prognostic factors associated
with OS (Table 4).
Discussion
Only limited amount of data are available on the prog-
nostic value of antiviral therapy in HCC patients under-
going TACE. Recently, the impact of antiviral therapy on
the survival after radical resection for HBV-related HCC
has been reported [25-28]. Most studies have indicated
that antiviral treatment can improve the prognosis after
surgery, including the increase of disease-free survival
and OS rates [25,28]. However, there is little information
about the effect of antiviral therapy on the long-term
outcome of HCC patients undergoing TACE.
For all of the cases in this study, patients with antiviral
treatment had significantly prolonged OS time compared
with those without antiviral treatment. The Cox multi-
variate analysis demonstrated that antiviral therapy was
an independent predictor for the OS time of HCC pa-
tients who underwent TACE. The results showed that
antiviral treatment conferred a survival benefit in pa-
tients with HBV-related HCC undergoing TACE.
Although not fully clarified [29], the role played by
antiviral therapy in prolonging the survival time mayinclude several aspects [28,30]. First, antiviral therapy
can decrease HBV replication and levels of HBV DNA,
which are regarded as risk factors for the development
of HCC [6]. In a study evaluating the relationship be-
tween HBV DNA levels and the survival of patients with
HCC treated by TACE, a high pre-TACE serum level of
HBV DNA was observed to be associated with poor OS
and rapid progression of HCC after TACE [31]. The
cause of deaths was not hepatitis exacerbation but can-
cer progression. Second, the incidence of HBV reactiva-
tion and the subsequent hepatitis can be decreased,
reducing the impairment of liver function and possibly
rendering patients to better tolerate further HCC treat-
ment. In the current study, 1 to 5 months after the ini-
tial TACE, there were 2 of 80 cases (2.5%) of HBV
reactivation in the antiviral therapy group and 20 of 144
(13.9%) in the non-antiviral therapy group (P < 0.001),
which is similar to the results of our previous study
[19,20]. In addition, 53.8% (43 of 80) of the patients in
the antiviral treatment group received more than one
session of TACE and 28.8% (23 of 80) of the patients re-
ceived post-TACE local ablation, which were higher than
the rates in the non-antiviral treatment group (Table 1).
Because the tumor stages and the baseline liver function
were comparable between the groups, it is reasonable to
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therapy patients accounted for the higher rate of mul-
tiple sessions of TACE or local ablation for HCC. This
result is consistent with those reported by Chan et al.
[26] and Toyoda et al. [32]. Third, although not well de-
fined, antiviral therapy may be associated with a reduced
risk of late-phase recurrence of HCC and therefore in-
crease OS rate. Although most patients in the current
study had intermediate- or advanced-stage diseases
(Table 1), multiple TACE sessions with subsequent local
ablation or resection may achieve favorable or even cur-
able effects in some selected cases [33].
In the current study, all patients had Child-Pugh grade
A liver function and ECOG PS grades 0–2. Because the
liver functional status and the physical status of patients
in this study were similar, we used the TNM staging sys-
tem in our analysis instead of the Barcelona Clinic Liver
Cancer (BCLC) staging system, in a manner similar to
that used by Chan et al. [26], who evaluated the effect of
antiviral treatment on the prognosis of HCC patients
undergoing major hepatectomy. For early-stage HCC,
surgical resection or radiofrequency ablation (RFA) are
regarded as first-line therapies, and liver transplantation
is an alternative. TACE is generally recommended for
intermediate- or advanced-stage diseases in most clinical
guidelines [34]. Actually, the majority of patients with
early-stage HCCs in our institute have been treated with
hepatectomy or RFA. However, some patients had con-
traindications to surgery or RFA, including tumor loca-
tion unsuitable for resection or ablation [14], and others
chose TACE after considering all the options [13]. Fur-
thermore, in the current study, we chose UICC TNM
staging (7th edition), which does not use the diameter of
the solitary tumor as a criterion in the classification of
T1 and T2 lesions. Thus, very large but solitary tumors,
which were unsuitable for resection, were categorized as
early-stage diseases. In early tumor stages (TNM stages I
and II), the median survival time for patients with anti-
viral treatment was significantly longer than that of
those with non-antiviral therapy (Figure 3A). The Cox
multivariate analysis revealed that antiviral treatment
was an independent factor for OS in patients with early-
stage tumors (Table 4). In patients with advanced-stage
HCCs (TNM stages III and IV), there was no significant
difference in OS between the antiviral and the non-
antiviral treatment groups (Figure 3B), and the Cox
multivariate analysis did not identify antiviral treatment
as a predictor for OS (Table 4). These findings were
somewhat similar to those reported by Chan et al. [26],
who evaluated the effect of antiviral treatment on the
prognosis of HCC patients undergoing major hepatec-
tomy. They stratified the patients according to the
American Joint Committee on Cancer (AJCC) TNM
stage and the status of major vascular invasion. Theauthors found that overall and disease-free survival rates
were increased after antiviral treatment in patients with
AJCC TNM stages I and II tumors or in those without
major vascular invasion, whereas no survival benefit was
observed for patients with stage III tumors or with
major vascular invasion. We postulated that the main
reason for the discrepancy in the results in different sub-
groups is that the long-term effect of NUCs has not yet
been determined in patients with advanced-stage tumors
who had short survival times. In the current study, the
median survival time was shorter in patients with
advanced-stage diseases than in those with early-stage
diseases (8.2 months versus 34.8 months), which may
help explain how the effect of antiviral therapy on sur-
vival differs depending on the HCC stage. The results in-
dicate that it is much more important to begin antiviral
treatment in HCC patients with early-stage tumors who
are expected to have longer survival time compared with
those with advanced-stage tumors.
Although the antiviral treatment did not show a sur-
vival benefit in patients with advanced-stage diseases in
the current study, that should not be interpreted as indi-
cating that there is no need for antiviral therapy in all
advanced-stage patients undergoing TACE. The current
study only included patients who had Child-Pugh grade
A liver function. Patients with severe post-TACE compli-
cations (including severe hepatitis or liver failure) were
excluded from this study. A prospective randomized
study demonstrated that preemptive lamivudine therapy
could effectively reduce the risk of hepatitis caused by
HBV reactivation and hepatic morbidity during TACE
[35]. Our previous study also revealed that anti-HBV
therapy can reduce the risk of HBV reactivation, thus re-
ducing the risk of liver failure in patients undergoing
TACE [20]. Therefore, we still recommend the close
monitoring of the patients with advanced-stage HCC
after TACE and the timely use of NUCs in the patients
with poor baseline liver function, the presence of cirrho-
sis, high levels of HBV replication, and/or HBV reactiva-
tion [18,20,36].
It should be noted that subsequent local thermal abla-
tion and/or subsequent resection after TACE was also a
positive contributing factor to OS. Nearly 30% (67 of
224) of the patients received other types of treatment
after TACE. Tables 1 and 3 show the fractions of
patients who underwent subsequent therapies. Patients
with early-stage HCCs received more subsequent therap-
ies than those with advanced-stage diseases; 15.5% (11 of
71) of the patients with early-stage HCCs underwent
resection after TACE, whereas in the patients with
advanced-stage diseases, the percentage was only 5.2%
(8 of 153); 40.8% (29 of 71) of the patients with early-
stage HCCs underwent RFA after TACE, whereas in the
patients with advanced-stage diseases, the percentage
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quent therapy in the antiviral and the non-antiviral
groups were not significantly different (P > 0.05, Tables 1
and 3). In addition, sex was also a risk factor for survival
in HCC patients in the current study, which is similar to
previous findings [37].
In this retrospective study, to eliminate the possible
adverse effects caused by treatment-related morbidity or
mortality shortly after TACE, we only chose the patients
with normal liver function before TACE (Child-Pugh
grade A) and excluded those with severe complications
shortly after TACE. Thus, we only evaluated the patients
who were likely to tolerate the TACE procedures well.
Therefore, the conclusions may not be generalizable to
all HCC patients undergoing TACE, including those
who cannot tolerate the chemoembolization well. Ad-
ministration of NUCs was not randomized into the two
groups in this retrospective cohort study, which may
have caused selection bias. Thus, well-designed pro-
spective randomized controlled trials are needed to con-
firm these findings.
In summary, our results demonstrated that antiviral
treatment was associated with prolonged OS time after
TACE for treatment of HBV-related HCC, especially in
relatively early-stage HCC.
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